Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort

Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort

Abstract Background The aim of the study was to analyze the relationship between pretreatment inflammatory biomarkers (IBs) and survival outcomes for patients with esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (neo‐CRT) and pembrolizumab. Methods Clinical varia...

Full description

Bibliographic Details
Main Authors: Wei‐Xiang Qi, Xiaoyan Wang, Chengqiang Li, Shuyan Li, Huan Li, Feifei Xu, Jiayi Chen, Shengguang Zhao, Hecheng Li
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Thoracic Cancer
Subjects:
absolute lymphocyte count
esophageal squamous cell carcinoma
neoadjuvant chemoradiotherapy
pathological complete response
pembrolizumab
Online Access:https://doi.org/10.1111/1759-7714.14898

Internet

https://doi.org/10.1111/1759-7714.14898

Similar Items